Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome of the Eustachian tube in patients with chronic obstructive Eustachian tube dysfunction and healthy individuals.

European journal of microbiology & immunology·2026
Same author

Health-related quality of life in amputees with a microprocessor-controlled prosthetic knee measured by the EQ-5D-5L.

Canadian prosthetics & orthotics journal·2026
Same author

Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer.

Immuno-oncology technology·2026
Same author

Neurotransmitter alterations in seasonal affective disorder.

Scientific reports·2026
Same author

"It's going to be huge": family member experiences of the transition into individualised housing for people with disability.

Disability and rehabilitation·2025
Same author

An updated review of international literature on the outcomes of individualized housing for people with disability and complex needs.

Disability and rehabilitation·2025
Same journal

Diagnostic and sex effects on frontostriatal brain wiring structural organization in early psychosis affective subjects compared to healthy controls.

Molecular psychiatry·2026
Same journal

Effects of family genetic risk scores and environmental factors on risk of schizophrenia and bipolar disorder.

Molecular psychiatry·2026
Same journal

Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.

Molecular psychiatry·2026
Same journal

Copy number variant scores are associated with cerebrovascular pathology in aging.

Molecular psychiatry·2026
Same journal

Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.

Molecular psychiatry·2026
Same journal

Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

Molecular psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.

R Lanzenberger1, P Baldinger, A Hahn

  • 1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. rupert.lanzenberger@meduniwien.ac.at

Molecular Psychiatry
|July 4, 2012
PubMed
Summary
This summary is machine-generated.

Electroconvulsive therapy (ECT) reduces serotonin-1A receptor binding in major depression patients. This finding offers insight into ECT

More Related Videos

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Related Experiment Videos

Last Updated: May 20, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Area of Science:

  • Neuroscience
  • Psychiatry
  • Radiology

Background:

  • Electroconvulsive therapy (ECT) is effective for severe treatment-resistant depression, but its neurobiological mechanisms are unclear.
  • The serotonin-1A receptor (5-HT(1A)) is implicated in antidepressant action and altered in depression.
  • Previous studies suggest a link between 5-HT(1A) function and antidepressant treatment response.

Purpose of the Study:

  • To investigate the effect of ECT on 5-HT(1A) receptor binding in patients with major depression.
  • To explore the neurobiological underpinnings of ECT's efficacy.

Main Methods:

  • 12 patients with treatment-resistant major depression underwent three positron emission tomography (PET) scans.
  • A selective radioligand, [carbonyl-(11)C]WAY100635, was used to measure 5-HT(1A) receptor binding.
  • PET scans were performed twice before and once after a course of ECT (10.08±2.35 sessions).

Main Results:

  • Ten patients (83%) responded to ECT.
  • A significant, widespread reduction in 5-HT(1A) receptor binding was observed in cortical and subcortical regions after ECT (P<0.05 corrected).
  • The most pronounced reductions were in the subgenual anterior cingulate cortex, orbitofrontal cortex, amygdala, hippocampus, and insula.

Conclusions:

  • ECT treatment leads to a global reduction in postsynaptic 5-HT(1A) receptor binding in major depression.
  • These findings suggest that alterations in 5-HT(1A) receptor binding are a key component of ECT's therapeutic effects.
  • The study provides novel insights into the neurobiological mechanisms of ECT in treating severe depression.